Group 1 - The core point of the news is the significant rise in the pharmaceutical sector in both A-shares and Hong Kong stocks, driven by the annual J.P. Morgan Global Healthcare Conference, which highlights the latest trends and expectations in the biotechnology and biopharmaceutical industries [1][3] - A notable external licensing deal was announced, where Chinese biopharmaceutical company Rongchang Bio entered into a collaboration with AbbVie worth up to $5.6 billion, including an upfront payment of $650 million, which positively impacted the stock prices of related companies [3] - The market is witnessing a surge in stock prices for dual-antibody concept stocks, with companies like Yiming Anke and Sanofi Guojian seeing significant increases of over 10.10% and 4% respectively [3] Group 2 - The external licensing of innovative drugs is becoming a crucial source of financing and revenue for innovative pharmaceutical companies, potentially increasing order volumes for contract research organizations (CROs) [3] - The CRO sector also experienced a price surge, with WuXi AppTec's stock rising over 6% and WuXi Biologics increasing by more than 5% [3] - Overall, the CRO index in A-shares saw an increase of over 5% as of January 13 [3] Group 3 - WuXi AppTec has raised its revenue forecast for the previous year for the third time, while WuXi Biologics expressed confidence in maintaining growth momentum through 2026 [4][5] - CITIC Securities published a report indicating optimism regarding Chinese companies' technological breakthroughs and international opportunities, highlighting a shift from a single market focus to global value creation [6] - Chinese pharmaceutical companies are becoming key players in global pharmaceutical innovation, leveraging a dual strategy of independent research and overseas business development [6]

Core Concept - The article discusses the transformative potential of AI for Science (AI4S) in reshaping China's technological landscape, emphasizing its role in enhancing foundational research efficiency and addressing critical industry challenges [3][9][10]. Group 1: AI4S Overview - AI4S represents a paradigm shift in scientific research, moving from a trial-and-error approach to a data and model-driven methodology, which is crucial for overcoming efficiency bottlenecks in foundational research [3][4]. - The integration of AI into foundational research is seen as a key factor for China's technological breakthroughs, particularly in critical sectors such as new materials, biomedicine, and semiconductors [3][9]. Group 2: Applications in New Materials - Fangda Carbon (600516.SH) and Jingtai Technology's collaboration exemplifies the application of AI4S in new materials, significantly reducing the research and development cycle from 2-3 years to 3-6 months [5]. - The partnership aims to optimize production processes and improve product yield by over 15%, showcasing the practical benefits of AI integration in traditional manufacturing [5]. Group 3: Applications in Biomedicine - Medicy (688202.SH) has redefined the drug development process through AI, achieving a significant reduction in the clinical research cycle by 40% and enhancing the accuracy of toxicity predictions to 92% [6][7]. - The company’s AI-driven platform integrates advanced technologies like Google’s AlphaFold3 and NVIDIA’s BioNeMo, allowing for rapid iteration in drug discovery and positioning China at the forefront of global pharmaceutical research [6][7]. Group 4: Applications in Semiconductors - DaoTech (300409.SZ) addresses the computational challenges in AI4S by developing specialized chips for atomic-level scientific calculations, which are essential for both materials and chip research [8]. - The establishment of the Hexi Atomic Computing Center enables a synergistic relationship between chip development and materials design, enhancing the efficiency of both fields [8]. Group 5: Market Dynamics and Future Outlook - The success of AI4S in China is attributed to a combination of industry demand, technological innovation, and supportive government policies, which collectively foster a conducive environment for AI integration in foundational research [9]. - Despite challenges such as data scarcity and talent shortages, AI4S presents unprecedented opportunities for China to advance in foundational research areas, potentially leading to a shift from a follower to a leader in global technology innovation [9][10].

杭州冬意正浓，运河之滨的富茂国际酒店内却暖意融融、春潮涌动。1月9日，杭州日报财经年会暨 二届天下杭商总会年会在此举行。 "变局 机遇 增长——'十五五'的前沿瞭望"圆桌论坛上，国家特聘专家、英飞特电子董事长华桂潮 拿起话筒，展示了AI如何让作物生长效率大幅提升；重庆华能控股董事长陈勇强调了"科技必须积极向 善"，分享企业用AI践行社会责任的实践；浙江建工地产集团副董事长陈健拆解了AI重塑房地产从设计 到管理的全链条；杭州合立机械董事长黄成兴讲述用AI传承老师傅几十年经验的探索……没有浮夸的 空想，只有扎实的实践，台下频频响起的掌声，是对杭商务实创新最好的共鸣。 创新，是杭商的精神内核。活动评出了年度杭商金砖人物1名、年度杭商卓越企业2家、年度杭商创 新企业8家和年度杭商品牌企业13家。 在杭商项目路演环节，7名杭商代表登上舞台，接受创投界评委的审阅。7个项目中既有硬科技突 破，也有模式创新；既有传统产业焕新，也有未来发展构想——它们虽尚处"微光"阶段，却蕴含着改变 行业的可能。 杭州因商而兴，因商而盛。广大杭商群体将以此次年会为新的起点，继续以微光守初心，以如炬照 征途。在不确定的时代里，做确定的自己；在变 ...

1月12日，百奥赛图涨14.87%，成交额4.25亿元。两融数据显示，当日百奥赛图获融资买入额2733.31万 元，融资偿还2783.88万元，融资净买入-50.57万元。截至1月12日，百奥赛图融资融券余额合计5579.88 万元。 资料显示，百奥赛图(北京)医药科技股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业 基地宝参南街12号院，成立日期2009年11月13日，上市日期2025年12月10日，公司主营业务涉及百奥赛 图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司 运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分 部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动 物，亦向客户授出若干模式动物的许可。抗体开发分部识别有潜力成为候选药物的抗体，并就潜在治疗 性抗体分子对外授权或与合作伙伴合作。创新药开发分部研发创新药，专注肿瘤学和自身免疫性疾病治 疗。 责任编辑：小浪快报 融资方面，百奥赛图当日融资买入2733.31万元。当前融资余额5579.88万元，占流通市值的2. ...

消息面上，1月9日，复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）上，首度公布 了其PD-L1 ADC HLX43治疗复发/转移性食管鳞癌（ESCC）的II期概念验证（POC）数据，本次发布的 数据初步验证了HLX43在经治的晚期ESCC患者中的治疗潜力，展现出令人鼓舞的疗效及良好的安全 性。HLX43已在非小细胞肺癌、宫颈癌、食管鳞癌及胸腺癌等多项实体瘤适应症中观察到持续且一致 的疗效和安全性趋势，其广谱抗肿瘤潜力正通过临床实践逐步得到验证，为后续拓展更多适应症奠定重 要基础。 智通财经APP获悉，复宏汉霖(02696)再涨超8%，截至发稿，涨8.05%，报69.8港元，成交额1864.08万港 元。 值得注意的是，第44届摩根大通医疗健康年会(JPM 2026)将于1月12–15日在美国旧金山举行。作为全球 医疗健康领域最具影响力的年度盛会之一，JPM大会被视为全球资本市场观察医药创新与产业趋势的重 要窗口。复宏汉霖执行董事兼首席执行官朱俊博士将于当地时间1月15日在大会上发表主题演讲，围绕 公司全球化2.0阶段的发展路径、创新管线布局及中长期战略规划，向国际投资人与产业界系统分享 ...

消息面上，1月9日，复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)上，首度公布了 其PD-L1ADC HLX43治疗复发/转移性食管鳞癌(ESCC)的II期概念验证(POC)数据，本次发布的数据初步 验证了HLX43在经治的晚期ESCC患者中的治疗潜力，展现出令人鼓舞的疗效及良好的安全性。HLX43 已在非小细胞肺癌、宫颈癌、食管鳞癌及胸腺癌等多项实体瘤适应症中观察到持续且一致的疗效和安全 性趋势，其广谱抗肿瘤潜力正通过临床实践逐步得到验证，为后续拓展更多适应症奠定重要基础。 值得注意的是，第44届摩根大通医疗健康年会(JPM2026)将于1月12–15日在美国旧金山举行。作为全球 医疗健康领域最具影响力的年度盛会之一，JPM大会被视为全球资本市场观察医药创新与产业趋势的重 要窗口。复宏汉霖执行董事兼首席执行官朱俊博士将于当地时间1月15日在大会上发表主题演讲，围绕 公司全球化2.0阶段的发展路径、创新管线布局及中长期战略规划，向国际投资人与产业界系统分享复 宏汉霖的最新进展与未来蓝图。 复宏汉霖(02696)再涨超8%，截至发稿，涨8.05%，报69.8港元，成交额1864.08万港 ...

Core Viewpoint - The Anhui Provincial Science and Technology Department has announced the fourth batch of "Technology Vice Presidents," with 11 individuals appointed to technology-oriented enterprises in Anqing, covering various fields such as biomedicine, functional membrane materials, and ecological agriculture [1] Group 1 - The "Technology Vice President" initiative is a flexible talent introduction policy aimed at injecting innovation into enterprises by assigning research talents from universities and research institutions to serve as technical vice presidents [1] - This program has resulted in a total of 63 provincial-level "Technology Vice Presidents" currently serving in enterprises within Anqing [1] - The initiative aims to bridge the gap between industry, academia, and research, enhancing regional innovation efficiency and overall competitiveness, thus contributing to high-quality local development [1] Group 2 - Since the implementation of this policy, Anqing has established a regular selection process for provincial-level technology vice presidents, facilitating a green channel for technology personnel from universities to enter enterprises [1] - A dynamic scheduling mechanism has been set up to monitor the service status of "Technology Vice Presidents," including service duration, joint talent cultivation, platform construction, technical cooperation, and technology achievement transformation [1] - The program emphasizes proactive communication and service support to effectively leverage the innovative leadership role of "Technology Vice Presidents," accelerating the integration of innovation chains, industrial chains, and talent chains [1]

◎本报记者 代小佩 "唯有持续深化基础与转化研究融合，才能不断推动血液学科高质量发展，让更多血液疾病患者迎来治 愈希望，为全球血液学科发展贡献中国智慧与中国方案。"中国工程院院士、中国医学科学院血液病医 院（中国医学科学院血液学研究所）所院长、细胞生态海河实验室常务副主任程涛近日在第六届中国血 液学科发展大会上表示。 来源：科技日报 此外，单细胞时空多组学技术的应用，构建起中国大人群免疫细胞多组学队列，实现从基因到病理模型 的多模态数据融合，为精准诊疗提供支撑。统计数据显示，2020—2024年，我国血液病领域SCI论文总 数达25058篇，较上一个五年增长2.18倍，研究实力显著提升。 临床转化落地见效 血液学科基础研究突破正加速转化为临床实效。例如，张磊团队参与研发的血友病B基因治疗药物"信 玖凝"，成为亚洲首款无条件上市的基因治疗药物，为患者带来福音。中国医学科学院血液病医院（中 国医学科学院血液学研究所）副所院长施均介绍，地中海贫血基因治疗同样取得重大进展，慢病毒载体 与CRISPR-Cas9技术使90%以上患者实现临床治愈，相关研究有望于2026年进入二期临床试验。 与此同时，政策红利与协同机制为基 ...

Group 1 - AbbVie has secured a licensing agreement with Rongchang Biopharma worth up to $5.6 billion, which includes an upfront payment of $650 million and potential milestone payments of up to $4.95 billion [1] - The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148, a bispecific antibody targeting PD-1 and VEGF, outside of Greater China [1] - RC148 is designed to enhance anti-tumor immune responses while inhibiting tumor-driven angiogenesis, and is currently undergoing clinical trials in China for various advanced malignancies [1] Group 2 - The PD-1/VEGF dual antibody market has seen increased interest, especially after Kangfang Biopharma's dual antibody demonstrated potential superiority over Merck's Keytruda in clinical trials [3] - Major pharmaceutical companies are investing in PD-1/VEGF dual antibodies, with significant licensing deals such as the $6.06 billion agreement between 3SBio and Pfizer, and the $11.1 billion collaboration between Bristol-Myers Squibb and BioNTech [3] - However, following disappointing overall survival data from Kangfang Biopharma's dual antibody, market enthusiasm for PD-1/VEGF dual antibodies has cooled, raising questions about the future potential of this therapeutic class [4] Group 3 - The recent licensing deal between Rongchang Biopharma and AbbVie may indicate a resurgence in interest in the PD-1/VEGF dual antibody space [4] - Kangfang Biopharma's partner, Summit, has submitted a new drug application to the FDA for its PD-1/VEGF dual antibody, targeting specific lung cancer patients, which could further influence market dynamics [4]

Market Overview - The Hong Kong stock market opened strongly on January 13, with the Hang Seng Index rising by 1.32%, the Hang Seng Tech Index increasing by 1.93%, and the China Enterprises Index up by 1.25% [1] - Notable gains were seen in tech stocks, with Alibaba rising nearly 5% and AI application stocks like Zhiyuan increasing by nearly 6%. The storage chip leader, Zhaoyi Innovation, saw its H-shares surge over 45% on its first trading day [1] Foreign Investment Outlook - According to Wind data, net inflows from southbound funds reached approximately HKD 32.694 billion, marking the highest weekly inflow in over a month and a half [2] - Major foreign institutions, including Goldman Sachs, Morgan Stanley, and UBS, have released positive market outlooks for 2026, driven by expectations of accelerated corporate profit growth, coordinated macro policies, and RMB appreciation [2] - The core drivers for the Chinese stock market's rise are shifting from "valuation recovery" in 2025 to "profit growth" in 2026, as per foreign institutions [2] Sector Recommendations - CITIC Securities suggests that the Hong Kong stock market could experience a second round of valuation recovery and performance revival in 2026, with a focus on sectors such as technology, healthcare, resources, consumer staples, paper, and aviation [2] - Western Securities highlights three factors driving the Hong Kong stock market's rebound: a weaker dollar encouraging international capital allocation to Hong Kong, RMB appreciation attracting Chinese capital back, and a recovery in the Chinese economy supported by inflation and potential debt relief policies [2] Market Sentiment and Trends - Huaxi Securities notes that the Hong Kong market has been underperforming compared to the A-share market, with a need for time to restore investor sentiment. The market has shown signs of recovery since late December, but the consensus for bullish sentiment remains to be solidified [3] - Huatai Securities indicates that the market sentiment index has entered a panic zone, historically leading to a significant increase in the probability of price rises in the following month [3] - ZheShang International maintains a cautious optimism regarding the market's mid-term outlook, despite a weak fundamental backdrop and a slight decline in the funding environment [3] Investment Opportunities - Industrial Securities recommends focusing on leading companies in the AI sector and dividend-paying assets in a low-interest-rate environment, including insurance, banking, energy, property management, and public utilities [4] - ZheShang International is optimistic about sectors benefiting from policy support, such as new energy, innovative pharmaceuticals, and AI technology, as well as low-valuation state-owned enterprises [4] - The 2026 spring performance of the Hong Kong market is expected to be driven by "AI applications, PPI improvement, and expanded domestic demand," with a focus on quality stocks in these areas [4] Company News - Rongchang Biopharmaceutical (09995) signed an exclusive licensing agreement with AbbVie for RC148, receiving an upfront payment of USD 650 million and potential milestone payments up to USD 4.95 billion [9] - WuXi AppTec (02359) forecasts a net profit of CNY 19.151 billion for 2025, representing a year-on-year increase of approximately 103% [9] - Dongfeng Motor Group (00489) reported cumulative vehicle sales of 1.8962 million units for 2025, a slight increase of 0.01% year-on-year [9] - Q Technology (01478) expects camera module sales to reach 45.938 million units for 2025, a year-on-year increase of 43.6% [9]